Blog

Caesarstone's Alleged Knowledge of the Silicosis Epidemic From 2015 to 2020

Artificial Stone Manufacturer: Caesarstone Ltd. and Caesarstone USA, Inc. : 2015 - 2020:

Spruce Point Capital Management Raises Concerns

In 2015, Spruce Point Capital Management issued a scathing report on Caesarstone, recommending a "Strong Sell" due to the growing number of lawsuits related to silicosis deaths and injuries among workers exposed to its products in Israel. The report highlighted the potential for unquantifiable product liability and increased regulatory scrutiny, posing a significant financial risk to the company.

Caesarstone Expands Despite Mounting Evidence

Despite the warnings, Caesarstone opened a new $100 million facility in the US in 2015, further increasing its global reach. Meanwhile, the silicosis epidemic in Israel worsened, with the number of cases allegedly attributed to Caesarstone reaching 40 by 2015.

Studies Confirm the Dangers

A 2015 study by Israeli researchers revealed that all 40 silicosis cases involved workers allegedly exposed to Caesarstone dust while dry-cutting and polishing the material for countertops. Notably, 23% of these workers also suffered from autoimmune diseases linked to silica exposure.

By 2016, the number of Israeli workers with alleged Caesarstone-related silicosis had more than doubled to 82. The researchers observed advanced forms of the disease in 85% of lung transplant patients, highlighting the severity of the health risks.

International Attention Raises Alarm

In 2016, an Israeli abstract presented at an international conference drew global attention to the "drastic rise in silicosis" within the country's stone industry, directly linking it to the increasing use of artificial quartz surfaces allegedly like Caesarstone. The abstract emphasized the short latency period of the disease, with many workers developing silicosis within 10-20 years of exposure.

Survival Rates Offer Mixed Signals

A 2017 study by Israeli researchers compared the survival rates of lung transplant recipients with silicosis and those with idiopathic pulmonary fibrosis (IPF). While the study showed no statistically significant difference in survival rates, it did suggest that silicosis patients generally fare well after lung transplants. This information, while potentially offering hope to affected workers, did not diminish the gravity of the underlying health risks allegedly associated with Caesarstone exposure.

Caesarstone's Alleged Knowledge and Responsibility

Throughout this period, Caesarstone's officers and directors were allegedly demonstrably aware of the growing body of evidence linking their product to silicosis and its devastating consequences. Despite this alleged knowledge, the company allegedly continued to prioritize business expansion and downplay the risks associated with its products.

This timeline underscores the severity of the silicosis epidemic allegedly linked to Caesarstone and raises serious concerns about the company's alleged ethical conduct and commitment to worker safety.